The Pharmacy Times® Parkinson Disease Resource Center is a comprehensive resource for clinical news and expert insights on treatments for Parkinson disease.
February 7th 2023
Pimavanserin is an atypical antipsychotic indicated for the treatment of Parkinson disease-associated hallucinations and delusions.
Study Results Show Moderate Drinking May Cause Cognitive DeclineJuly 19th 2022
Data indicate that consumption of 7 or more units of alcohol per week is associated with higher iron levels in the brain, which has been linked to Alzheimer and Parkinson diseases.
Clinical Overview: Dhivy for Treating Parkinson Disease or its Manifestations Due to Viral, Environmental ToxinsApril 18th 2022
Dhivy is a levodopa/carbidopa combination formulation approved by the FDA in November 2021 for the treatment of Parkinson disease or manifestations due to viral or environmental exposures.
Chronic Gut Inflammation Associated With Onset of Parkinson DiseaseJune 10th 2021
The results of the study are consistent with several large-scale epidemiological studies that show an association between Parkinson and inflammatory bowel diseases, such as ulcerative colitis and Crohn disease.
Study: Differences in Walking Patterns Could Predict Type of Cognitive Decline in Older AdultsFebruary 23rd 2021
The study compared step impairments across the cognitive spectrum, including people with subjective cognitive impairment, Parkinson disease, mild cognitive impairment, Alzheimer disease, Lewy body dementia, and frontotemporal dementia, as well as cognitively healthy controls.
The Impact of Physical Activity on Parkinson Disease ProgressionOctober 23rd 2020
Research has also shown that patients with Parkinson disease who are able to engage in physical activity can potentially improve the motor and non-motor symptoms associated with the disease.
Monday Pharmaceutical Mystery: What Is Causing an Outbreak of Parkinson Disease in Young People?September 22nd 2020
Seven cases of young people with stiffness throughout their body and an inability to speak presented to hospitals in different cities throughout the country, with seemingly no link between them.
New Treatment Available for “Off” Episodes in Patients with Parkinson DiseaseOctober 16th 2019
Kyowa Kirin’s istradefylline (Nourianz) is now available in the United States as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) that are experiencing “off” episodes.